Alexis Kaushansky

Alexis Kaushansky

Auto-generated profile, based on publicly available information

Alexis Kaushansky

University of Washington, Pathobiology Doctoral Program, Department of Global Health, School of Medicine, Seattle, WA, USA; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA; University of Washington, Department of Pediatrics, School of Medicine, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2019 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
HKHeather S. Kain
Heather S. Kain
EGElizabeth K. K. Glennon
Elizabeth K. K. Glennon
KVKamalakannan Vijayan
Kamalakannan Vijayan
NANadia Arang
Nadia Arang
ADAlyse N. Douglass
Alyse N. Douglass
AKAlexis Kaushansky
Alexis Kaushansky
The facets of host control during Plasmodium liver infection remain largely unknown. We find that the SLC7a11-GPX4 pathway, which has been associated with the production of reactive oxygen species, lipid peroxidation, and a form of cell death called ferroptosis, plays a critical role in control of Plasmodium liver stage infection. Specifically, blocking GPX4 or SLC7a11 dramatically reduces Plasmodium liver stage parasite infection. In contrast, blocking negative regulators of this pathway, NOX1 and TFR1, leads to an increase in liver stage infection. We have shown previously that increased levels of P53 reduces Plasmodium LS burden in an apoptosis-independent manner. Here, we demonstrate that increased P53 is unable to control parasite burden during NOX1 or TFR1 knockdown, or in the presence of ROS scavenging or when lipid peroxidation is blocked. Additionally, SLC7a11 inhibitors Erastin and Sorafenib reduce infection. Thus, blocking the host SLC7a11-GPX4 pathway serves to selectively elevate lipid peroxides in infected cells, which localize within the parasite and lead to the elimination of liver stage parasites.

1 October 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
NPNathan Heath Patterson
Nathan Heath Patterson
MTMichael Tuck
Michael Tuck
ALAdam Lewis
Adam Lewis
AKAlexis Kaushansky
Alexis Kaushansky
JNJeremy L. Norris
Jeremy L. Norris
RCRichard M. Caprioli
Richard M. Caprioli

19 October 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
LWLing Wei
Ling Wei
JAJack Adderley
Jack Adderley
DLDidier Leroy
Didier Leroy
DDDavid H. Drewry
David H. Drewry
DWDanny W. Wilson
Danny W. Wilson
CDChristian Doerig
Christian Doerig
Host-directed therapy (HDT) is gaining traction as a strategy to combat infectious diseases caused by viruses and intracellular bacteria, but its implementation in the context of parasitic diseases has received less attention. Here, we provide a brief overview of this field and advocate HDT as a promising strategy for antimalarial intervention based on untapped targets. HDT provides a basis from which repurposed drugs could be rapidly deployed and is likely to strongly limit the emergence of resistance. This strategy can be applied to any intracellular pathogen and is particularly well placed in situations in which rapid identification of treatments is needed, such as emerging infections and pandemics, as starkly illustrated by the current COVID-19 crisis.

5 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDiego Rodríguez-Hernández
Diego Rodríguez-Hernández
KVKamalakannan Vijayan
Kamalakannan Vijayan
RZRachael Zigweid
Rachael Zigweid
MFMichael K. Fenwick
Michael K. Fenwick
BSBanumathi Sankaran
Banumathi Sankaran
MGMorten Grøtli
Morten Grøtli
Drugs targeting multiple stages of the Plasmodium vivax life cycle are needed to reduce the health and economic burdens caused by malaria worldwide. N-myristoyltransferase (NMT) is an essential eukaryotic enzyme and a validated drug target for combating malaria. However, previous PvNMT inhibitors have failed due to their low selectivity over human NMTs. Herein, we apply a structure-guided hybridization approach combining chemical moieties of previously reported NMT inhibitors to develop the next generation of PvNMT inhibitors. A high-resolution crystal structure of PvNMT bound to a representative selective hybrid compound reveals a unique binding site architecture that includes a selective conformation of a key tyrosine residue. The hybridized compounds significantly decrease P. falciparum blood-stage parasite load and consistently exhibit dose-dependent inhibition of P. vivax liver stage schizonts and hypnozoites. Our data demonstrate that hybridized NMT inhibitors can be multistage antimalarials, targeting dormant and developing forms of liver and blood stage.

1 July 2021 in Chemical Reviews
Verified
Journal Article
Closed access
KVKamalakannan Vijayan
Kamalakannan Vijayan
LWLing Wei
Ling Wei
EGElizabeth K. K. Glennon
Elizabeth K. K. Glennon
CMChrista Mattocks
Christa Mattocks
NBNatasha Bourgeois
Natasha Bourgeois
AKAlexis Kaushansky
Alexis Kaushansky

12 August 2020 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
FMFred D. Mast
Fred D. Mast
ANArti T. Navare
Arti T. Navare
ASAlmer M. van der Sloot
Almer M. van der Sloot
JCJasmin Coulombe-Huntington
Jasmin Coulombe-Huntington
MRMichael P. Rout
Michael P. Rout
JAJohn D. Aitchison
John D. Aitchison
With the rapid global spread of SARS-CoV-2, we have become acutely aware of the inadequacies of our ability to respond to viral epidemics. Although disrupting the viral life cycle is critical for limiting viral spread and disease, it has proven challenging to develop targeted and selective therapeutics. Synthetic lethality offers a promising but largely unexploited strategy against infectious viral disease; as viruses infect cells, they abnormally alter the cell state, unwittingly exposing new vulnerabilities in the infected cell. Therefore, we propose that effective therapies can be developed to selectively target the virally reconfigured host cell networks that accompany altered cellular states to cripple the host cell that has been converted into a virus factory, thus disrupting the viral life cycle.